scholarly journals Safety, Efficacy, and Patient Acceptability of Montelukast in Exercise-Induced Asthma

2012 ◽  
Vol 4 ◽  
pp. CMT.S7389
Author(s):  
S. Kansra ◽  
A. Mazzei ◽  
J. Bhatt

Exercise-induced bronchoconstriction (EIB) can be a troublesome problem in asthmatic children and in some children without asthma. Self-reported exercise related symptoms should be verified formally. EIB is mediated by changes in temperature and humidity in the airway and is secondary to release of several mediators of the bronchoconstriction including leukotrienes. Montelukast as a leukotriene receptor antagonist offers protection against but does not completely ameliorate EIB. Regular use does not appear to lead to tolerance. Nightmares, abdominal pain, fever, nausea and aggressiveness are commonly described side effects; however, the overall safety profile of montelukast is good and does not change with long term use. There are individual differences in response to montelukast for protection against EIB. Bronchoconstriction triggered by exercise responds to cessation of exercise in its natural course. Due to its pharamacokinetic profile, montelukast may be more useful as a prophylaxis than to relieve symptoms.

1999 ◽  
Vol 43 (3) ◽  
pp. 185-186
Author(s):  
JONATHAN A. LEFF ◽  
WILLIAM W. BUSSE ◽  
DAVID PEARLMAN ◽  
EDWIN A. BRONSKY ◽  
JAMES KEMP ◽  
...  

Engrami ◽  
2020 ◽  
Vol 42 (2) ◽  
pp. 57-68
Author(s):  
Nikola Trajanović

A novel group of medications, dual orexin receptor antagonists, emerged as a competent group that challenges current first-line hypnotics. They have relatively infrequent and mostly well-tolerated side effects, primarily in the form of residual somnolence, fatigue and nightmares/disturbing dreams. The advantage over conventional hypnotics stems from the specifics of their target receptors, which translates into lack of tolerance after long term use and good safety profile. They are particularly favoured in some specific populations, including the elderly. Ongoing and future studies are set to explore their effect on selected conditions, such as addiction and psychiatric disorders, dementias, perimenopausal condition and circadian rhythm disorders, to name a few.


PEDIATRICS ◽  
1980 ◽  
Vol 66 (1) ◽  
pp. 109-114
Author(s):  
R. Yeung ◽  
G. M. Nolan ◽  
H. Levison

The effect of 40 µg of SCH 1000 (ipratropium bromide, an anticholinergic agent) on bronchodilation and suppression of exercise-induced bronchospasm (EIB) was compared with 400 µg of fenoterol and a placebo in a single-blind controlled study. Twenty-seven randomly selected asthmatic children performed a standardized treadmill exercise challenge and the 17 children who were shown to have EIB continued in the study. Pulmonary function was evaluated before and after drug administration and exercise. When individual results were analyzed and grouped according to the responsiveness of EIB to the drugs, two patterns emerged: (1) the EIB was more severe in those (6/17) children who did not respond to either drug than in the rest of the children; (2) the resting pulmonary function was significantly better in the children (4/17) who responded to both drugs than in those (7/17) who responded to fenoterol alone. In conclusion SCH 1000 was shown to be an effective bronchodilator comparable to, but no better than, fenoterol. It had minimal side effects. As an EIB inhibitor it depended on relatively normal base line pulmonary function and only a moderate deterioration following exercise, whereas fenoterol depended on the exercise response alone. Although anticholinergic drugs are not very extensively used, SCH 1000 may be useful in some patients where the β2 adrenergic drugs cause significant side effects or are contraindicated.


2015 ◽  
Vol 8 ◽  
pp. A6
Author(s):  
Demet Can ◽  
Semiha Bahceci Erdem ◽  
Hikmet Tekin Nacaroglu ◽  
Canan Sule Unsal Karkiner ◽  
Ilker Gunay

2021 ◽  
Author(s):  
Cheryl A. Frye ◽  
Jennifer K. Torgersen ◽  
Vincent F. Lembo ◽  
Kelly Drew

The clinical literature and recent studies in our laboratory using rodent models demonstrate that there are individual differences in androgens’ pleiotropic effects across the lifespan that need to be better understood. The question to address that challenges the field is that levels of androgens (current and/or prior) may not drive differing responses to androgens. The clinical example of Post-finasteride Syndrome, in which side-effects persist long after treatment is discontinued, supports investigations of this novel question relating to long-term effects of androgen manipulations, independent of existing levels of androgens.


Sign in / Sign up

Export Citation Format

Share Document